Search

News type
1756 - 1764 of 2152 results

“Behind every research project are scientists who care deeply about bringing change to improve the lives of people with CF”

Feature - Published Date:

For many people with CF the increased socialising around the festive period can increase anxiety about developing hard to treat lung infections, that could mean long courses of antibiotics and time spent in hospital. Cystic Fibrosis Trust is funding research to develop new treatments for those infections. We spoke to CF researcher Dr Vitor Mendes about his work designing new treatments for non-tuberculous mycobacteria (NTM) infections and his festive wishes for the CF community. 

Search result from the Trials Tracker

The CF STORM Trial: A trial investigating the effects of stopping nebulised therapies for people on Kaftrio

CTAP badge
Study details

For people with cystic fibrosis (pwCF), how to reduce treatment burden has been identified as the top priority research question. Daily nebulised treatments were identified by pwCF as burdensome. The CF STORM trial will recruit pwCF age 6 years and above that have been established on Kaftrio™ therapy. They will have an equal chance of being allocated to either stop or continue their daily nebulised muco-active therapies (dornase alfa, hypertonic saline or both). The trial is designed to provide confidence that stopping these nebulisers does not result in a significant decline in lung function over 12 months. The trial will...

Study updates

Early results from CF STORM were released in October 2025. To find out more about these early results and what we know so far, read our blog with Dr Gwyneth Davies, the co-Chief Investigator of the study.

The full results will be released in Summer 2026.

Click below to find out more. Find out more
Trials Tracker ID
TT005796
Age range
6+
Trial status
Recruitment complete
Therapeutic approach
Other

Gut Research Advancing a Mechanistic and Personalised Understanding of Symptoms in Cystic Fibrosis (GRAMPUS-CF) Strategic Research Centre

The Trust is funding a Strategic Research Centre that aims to link the specific gut symptoms people with CF experience to what changes are taking place within their intestines. By increasing understanding of the cause of gut symptoms, the researchers hope that this could lead to more tailored medicines to treat people with CF in the future. The research is led by Professor Alan Smyth at University of Nottingham.

Research workshops

Cystic Fibrosis Trust research workshops and how they develop research in lesser known areas

Our highlights: Looking back at 2025

Blog - Published Date:

As 2025 comes to a close, we look back on a year of challenges and triumphs. From scientific breakthroughs to incredible fundraising challenges, here are some of the moments that defined our year.

Search result from the Trials Tracker

HIT CF and CHOICES: a study investigating a new triple combination CFTR modulator therapy based on organoid responsiveness in people with CF who have rare CFTR gene mutations

CTAP badge
Study details

Part 1 of study (now closed): HIT CF (Human Individualised Therapy in CF). Part 1 of the study (HIT CF) involved the collection of rectal biopsies from people with CF who have rare CFTR mutations and are not eligible for taking Kaftrio®. These rectal biopsies were used to grow organoids (aka ‘mini-organs’), and a new triple combination CFTR modulator therapy was tested for effectiveness on these organoids in a laboratory before assessing the medication directly in people with CF. This CFTR modulator therapy consists of dirocaftor (CFTR potentiator), posenacaftor (CFTR corrector) and nesolicaftor (CFTR amplifier), developed by FAIR Therapeutics –...

Click below to find out more. Find out more
Trials Tracker ID
TT002006
Age range
18 years and older
Length of participation
42 weeks
Trial status
Recruitment complete
Therapeutic approach
Restore CFTR Function